Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05658445
Other study ID # As
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 1, 2023
Est. completion date March 1, 2023

Study information

Verified date December 2022
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The definition of recurrent spontaneous abortion (RSA) has changed over the years, and most societies now advocate defining RSA as two or three consecutive or discontinuous miscarriages with the same sexual partner before 24 weeks gestation In recent years, the incidence of this disease has been on the rise, occurring in about 1%- 5% of pregnancy in women at childbearing age, and the success rate of second pregnancy in RSA females has been significantly reduced The etiology of RSA is extremely complex, including anatomical factors, genetic factors, endocrine factors, infectious and immune factors, and pre-thrombosis etiology. However, the cause of the disease is unclear in half of patients and known as unexplained recurrent spontaneous abortion (URSA)


Description:

- MicroRNA (miRNA) is a kind of non-coding single-stranded RNA molecule encoded by endogenous genes with a length of about 22 nucleotides . MiRNA negatively regulates gene expression mainly by binding to the 3 'untranslated region (3' UTR) of target mRNA to degrade the target mRNA or inhibit its translation . In recent years, there have been numerous reports about miRNA's involvement in the pathogenesis of RSA, and many of them have focused on how miRNA regulates trophoblast function. - Additionally, microRNA (miR)-410-5p has been discovered to serve as oncogenes and tumor suppressors altering cell functions in numerous ways including proliferation, apoptosis, biochemistry metabolism, and inflammatory responses in different human malignancies, such as liver cancer, pancreatic cancer, colon cancer, and non-small cell lung cancer. Recent studies showed that miR-410-5p may be involved in the non-cancerous disorder processes such as RSA . Overexpression of miR-410-5p in trophoblast cells inhibited the polarization of M2 macrophages, while knockdown of miR-410-5p was beneficial to recruitment of trophoblast cell and promoted the polarization of M2 macrophages. Furthermore, MicroRNA (miR)-410-5p was discovered to bind with 3'-UTR of ITGA6 . - The adhesion molecule integrin alpha-6 (ITGA6, CD49f), a member of the integrin family, is overexpressed in many cancers and enhances cell movement and signal output . - Down-regulation of ITGA6 changed the biological function of trophoblast cells, inhibited cell proliferation, invasion and migration, and induced apoptosis. ITGA6 may affect the biological functions of trophoblast cells by regulating PI3K/AKT and MAPK signaling pathways. MAPK signaling promote apoptosis through inducing releasing of cytochrome c, which in turn induces further caspase activation (caspase-9 and the effector caspases-3, -6, and -7) . - Baculoviral IAP Repeat Containing 7(BIRC7) encodes the protein Livin which is a member of the inhibitor of apoptosis protein (IAP) family. Livin consists of a single baculoviral IAP repeat domain (BIR) and a RING domian at the C-terminus. The protein inhibits apoptosis by inhibiting proteolytic activation of capsases. - Currently, the interaction of BIRC7 and NK cells in endometrium/decidual remains unknown. BIRC7 in decidua cell may possess the ability to prevent NK cells from killing embryonic and extraembryonic cells, decreased level of BIRC7 and increased number of NK cells in the RM group attribute to the occurrence of miscarriage


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 86
Est. completion date March 1, 2023
Est. primary completion date January 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 30 Years
Eligibility Inclusion Criteria: maternal age is between 20 to 30 years and Gestational age before abortion less than 24 weeks. Female with unexplained two or three consecutive or discontinuous miscarriages with the same sexual partner Exclusion Criteria: 1. Female with one miscarriage 2. Female with explained causes of miscarriage 3. Female with cancer 4. Female with chronic illness. 5. Pregnant women above 30

Study Design


Related Conditions & MeSH terms


Intervention

Other:
evacuation
after complete evacuation of uterus follow abortion

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Nesma Gamal

Outcome

Type Measure Description Time frame Safety issue
Primary Define a novel hypothesis that may explain the aetiology of URSA within 3 years
See also
  Status Clinical Trial Phase
Completed NCT01670929 - Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage Phase 4
Completed NCT01232465 - Impact of Sperm DNA Integrity on In Vitro Cycles N/A
Completed NCT00400387 - Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss Phase 3
Completed NCT00606905 - Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage N/A
Active, not recruiting NCT04360564 - RPL: Interval to Live Birth and Adverse Perinatal Outcomes
Completed NCT02823743 - RECAB-ASA; Treatment of Recurrent Abortion With Aspirin N/A
Completed NCT00721591 - Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy N/A
Withdrawn NCT01718340 - Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia Phase 4
Completed NCT01788540 - Intralipid for Recurrent Miscarriage Phase 4
Completed NCT04148638 - Explore the Role of NLRP7 in the Regulation of Progestereone Induced Decidualization of Human Endometrial Stroma Cells
Completed NCT02223221 - Effects of PGS in Infertile Female Patients With RPL N/A
Recruiting NCT04064931 - Nutritional Deficiencies About Recurrent Miscarriage
Completed NCT02761772 - Early Pregnancy Cohort and Preimplantation Factor